DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Litton J, Rugo H, Ettl J. et al.
EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physicianʼs choice of therapy in patients with advanced germline BRCA-mutation breast cancer. San Antonio Breast Cancer Symposium 2017; Abstract GS6-07.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.